Cardiovascular toxicities of CAR T-cell therapy
NP Patel, PG Doukas, LI Gordon, N Akhter - Current oncology reports, 2021 - Springer
Purpose of review This review provides a contemporary overview of current studies outlining
the incidence and characteristics of CAR T-cell cardiotoxicity in an effort to identify future …
the incidence and characteristics of CAR T-cell cardiotoxicity in an effort to identify future …
Adverse cardiac effects of car t-cell therapy: characteristics, surveillance, management, and future research directions
PJ Dalal, NP Patel, MJ Feinstein… - Technology in Cancer …, 2022 - journals.sagepub.com
This review summarizes the current literature on the adverse cardiac effects of CAR T-cell
therapy. Case reports and series suggest that major adverse cardiovascular events are not …
therapy. Case reports and series suggest that major adverse cardiovascular events are not …
[HTML][HTML] Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study
M Camilli, M Viscovo, T Felici, L Maggio, F Ballacci… - Cardio-Oncology, 2024 - Springer
Abstract Aims Chimeric Antigen Receptor-T (CAR-T) cell infusion is a rapidly evolving
antitumor therapy; however, cardiovascular (CV) complications, likely associated with …
antitumor therapy; however, cardiovascular (CV) complications, likely associated with …
Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
Chimeric antigen receptor (CAR)-T cell therapy is the next revolutionary advance in cancer
therapy. By using ex vivo engineered T cells to specifically target antigens, a targeted …
therapy. By using ex vivo engineered T cells to specifically target antigens, a targeted …
CAR T cell therapy–related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?
CD19-specific chimeric antigen receptor (CAR) T cell therapies have shown remarkable
early success in highly refractory and relapsing hematological malignancies. However, this …
early success in highly refractory and relapsing hematological malignancies. However, this …
CAR T-cell cancer therapies: do not forget the heart
The registry data presented by Mahmood et al. 9 demonstrate that CAR T-cell recipients
experience severe cardiac events (SCEs) at significant rates. In these patients …
experience severe cardiac events (SCEs) at significant rates. In these patients …
Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives
Chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment of
patients with relapsed and refractory hematologic malignancies and is increasingly …
patients with relapsed and refractory hematologic malignancies and is increasingly …
Incidence of MACE in patients treated with CAR-T cell therapy: a prospective study
Background Previous retrospective studies have shown that chimeric antigen receptor T
(CAR-T) cell therapy may be associated with major adverse cardiovascular events (MACE) …
(CAR-T) cell therapy may be associated with major adverse cardiovascular events (MACE) …
[HTML][HTML] Cytokines are at the heart of it: cytokine release syndrome underlies cardiovascular effects of CAR T cell
AB Catino - Cardio Oncology, 2020 - jacc.org
Chimeric antigen receptor (CAR) T cell therapy has emerged as an extremely promising
therapy for patients with refractory and relapsing hematological malignancies, primarily B …
therapy for patients with refractory and relapsing hematological malignancies, primarily B …
Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis
M Guo, X Wang, S Xiao, A Liu, T Xu, C Huan… - Clinical and …, 2023 - Springer
As a novel anticancer therapy, chimeric antigen receptor T (CAR T) cell therapy may lead to
cardiotoxic reactions. However, the exact incidence remains unclear. Our study aimed to …
cardiotoxic reactions. However, the exact incidence remains unclear. Our study aimed to …